A phase I, randomized, double-blind, placebo-controlled study of combination therapy doublet, PTI-808 and PTI-801
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2018
At a glance
- Drugs PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Proteostasis Therapeutics
- 17 Oct 2018 According to a Proteostasis Therapeutics media release, The fourth and highest dose cohort, patients receiving PTI-801 (400 mg) and PTI-808 (300 mg), is ongoing, with data expected in the first quarter of 2019.
- 17 Oct 2018 Preliminary results (n=21) presented in a Proteostasis Therapeutics media release.
- 14 Mar 2018 According to a Proteostasis Therapeutics media release, initial results are expected in the middle of 2018.